GSK3A
Glycogen synthase kinase-3 alpha
As of the edition of 20 October 2026, GSK3A (glycogen synthase kinase-3 alpha, UniProt P49840) has 3 drugs tested at it and 10 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49840
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 2
- Disease areas
- Nervous system; Mental health; Cancer; Inherited and neonatal; Injuries; Blood and lymph; Nutrition and metabolism; Chemically induced
- Registered trials of its drugs
- 68
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lithium carbonate | Marketed | Phase 4 | none listed |
| LY-2090314 | Stopped | Phase 2 | none listed |
| Lithium citrate anhydrous | Marketed | No phase stated | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 8 |
| Total on the list | 10 |
The other 8 companies at GSK3A
In the product10 companies in all; 8 are not named here, and no score is.
See the 10 companies at GSK3A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.